Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

CHOICE-CLOSURE | Which Closure Device for TAVR is Better?

In patients who undergo transcatheter aortic valve replacement (TAVR) through transfemoral access, a closure device based on plug technology (MANTA VCD) is associated with a higher chance of access-related complications, but with shorter hemostasis time compared with a device with suture technology such as ProGlide VCD.

¿Cuál es el mejor tipo de dispositivo de cierre para el acceso del TAVI?

Nowadays, most patients undergo TAVR through transfemoral access. Percutaneous closure of the access bears multiple advantages for both patient and operator. However, there are several designs in the market, and it remains unclear which one is the most effective.

CHOICE-CLOSURE was a multicenter study in which patients scheduled for TAVR through femoral access were randomized to a device based on plug technology (Manta) vs. a device based on suture technology (ProGlide).

The protocol did not allow for an extra device when using Manta. In the case of ProGlide, two devices were used (at hours 10 and 14, respectively) and, if necessary, a small plug to help both PloGlide could be used (for example, AngioSeal).

The primary endpoint was major and minor access-related complications during the index hospitalization. The secondary endpoints included access-related bleeding, device failure to achieve hemostasis, and time to hemostasis.

About 516 patients were included and randomized, with a mean STS score of 4.1 ± 2.9% and 7.6% of associated peripheral vascular disease.


Read also: Suture-Based Percutaneous Closure vs. Plug for Large Arteriotomies.


The primary endpoint was reached in 19.4% of the population treated with Manta, and in 12% of those who received ProGlide (p = 0.029). Bleeding rates were better with ProGlide, while device efficacy was similar between both.

In terms of time to hemostasis, Manta was 3x faster (80 vs. 240 sec.; p < 0.001).

Conclusion

In patients who underwent transfemoral TAVR, the Manta device was linked to more vascular complications but reached hemostasis faster than two ProGlide. The time difference in relative terms seems a lot, but in absolute numbers it was barely over two minutes.

CIRCULATIONAHA-121-057856

Original Title: Comparison of a Pure Plug-Based versus a Primary Suture-Based Vascular Closure Device Strategy for Transfemoral Transcatheter Aortic Valve Replacement: The CHOICE-CLOSURE Randomized Clinical Trial.

Reference: Mohamed Abdel-Wahab et al. Circulation. 2021 Nov 5. doi: 10.1161/CIRCULATIONAHA.121.057856. Online ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...